Janus Henderson Group PLC Biomarin Pharmaceutical Inc Transaction History

Janus Henderson Group PLC

  • $187 Billion
  • Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 14,051 shares of BMRN stock, worth $911,628. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,051
Previous 14,051 -0.0%
Holding current value
$911,628
Previous $1.16 Million 14.62%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$74.43 - $92.22 $50.8 Million - $62.9 Million
-682,467 Reduced 97.98%
14,051 $1.16 Million
Q1 2024

May 15, 2024
SELL
$83.81 - $99.0 $175 Million - $207 Million
-2,093,825 Reduced 75.04%
696,518 $60.8 Million
Q4 2023

Feb 14, 2024
SELL
$76.22 - $98.51 $48.3 Million - $62.5 Million
-634,196 Reduced 18.52%
2,790,343 $269 Million
Q3 2023

Nov 14, 2023
BUY
$85.07 - $94.48 $2.97 Million - $3.3 Million
34,893 Added 1.03%
3,424,539 $303 Million
Q2 2023

Aug 14, 2023
SELL
$86.68 - $100.3 $4.13 Million - $4.78 Million
-47,638 Reduced 1.39%
3,389,646 $294 Million
Q1 2023

May 15, 2023
SELL
$87.74 - $117.27 $39.6 Million - $52.9 Million
-451,160 Reduced 11.6%
3,437,284 $334 Million
Q4 2022

Feb 14, 2023
SELL
$80.93 - $108.63 $19.5 Million - $26.2 Million
-241,280 Reduced 5.84%
3,888,444 $402 Million
Q3 2022

Nov 14, 2022
SELL
$82.16 - $96.94 $5.88 Million - $6.93 Million
-71,509 Reduced 1.7%
4,129,724 $350 Million
Q2 2022

Aug 15, 2022
SELL
$71.48 - $86.85 $11.3 Million - $13.8 Million
-158,551 Reduced 3.64%
4,201,233 $348 Million
Q1 2022

May 16, 2022
BUY
$74.28 - $92.69 $34.6 Million - $43.2 Million
465,547 Added 11.95%
4,359,784 $336 Million
Q4 2021

Feb 14, 2022
SELL
$71.72 - $91.47 $3.9 Million - $4.98 Million
-54,444 Reduced 1.38%
3,894,237 $344 Million
Q3 2021

Nov 16, 2021
SELL
$74.77 - $85.47 $411,907 - $470,854
-5,509 Reduced 0.14%
3,948,681 $305 Million
Q2 2021

Aug 16, 2021
SELL
$75.51 - $84.79 $78.5 Million - $88.1 Million
-1,039,465 Reduced 20.82%
3,954,190 $330 Million
Q1 2021

May 17, 2021
SELL
$74.73 - $90.69 $51.8 Million - $62.9 Million
-693,287 Reduced 12.19%
4,993,655 $377 Million
Q4 2020

Feb 16, 2021
BUY
$72.61 - $90.2 $34.3 Million - $42.6 Million
472,232 Added 9.06%
5,686,942 $499 Million
Q3 2020

Nov 16, 2020
BUY
$71.87 - $131.03 $260 Million - $474 Million
3,618,749 Added 226.74%
5,214,710 $397 Million
Q2 2020

Aug 14, 2020
BUY
$79.55 - $124.22 $36.9 Million - $57.6 Million
463,882 Added 40.98%
1,595,961 $197 Million
Q1 2020

May 14, 2020
BUY
$71.37 - $96.85 $77 Million - $104 Million
1,078,721 Added 2021.67%
1,132,079 $95.7 Million
Q4 2019

Feb 18, 2020
SELL
$64.27 - $86.37 $96,662 - $129,900
-1,504 Reduced 2.74%
53,358 $4.51 Million
Q3 2019

Nov 14, 2019
SELL
$67.4 - $85.11 $50,617 - $63,917
-751 Reduced 1.35%
54,862 $3.7 Million
Q2 2019

Jul 31, 2019
BUY
$80.35 - $93.9 $799,723 - $934,586
9,953 Added 21.8%
55,613 $4.76 Million
Q1 2019

Apr 30, 2019
BUY
$84.2 - $98.62 $68,370 - $80,079
812 Added 1.81%
45,660 $4.05 Million
Q4 2018

Feb 06, 2019
SELL
$80.14 - $106.07 $12,581 - $16,652
-157 Reduced 0.35%
44,848 $3.82 Million
Q3 2018

Nov 09, 2018
BUY
$93.92 - $105.72 $47,053 - $52,965
501 Added 1.13%
45,005 $4.37 Million
Q3 2017

Nov 14, 2017
BUY
$80.6 - $94.95 $912,230 - $1.07 Million
11,318 Added 34.1%
44,504 $0
Q2 2017

Aug 17, 2017
BUY
N/A
33,186
33,186 $3.01 Million

Others Institutions Holding BMRN

# of Institutions
638
Shares Held
178M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email